Switch theme
Sign up to access all valuation multiples
PEPTONIC medical AB is a pharmaceutical company. It is engaged in developing oxytocin-based products for the treatment of menopausal symptoms, such as vaginal atrophy and vaginal dryness. Oxytocin is for medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. The company is based in Sweden.
2
Last FY Revenue $2.8M
Last FY EBITDA -$5.4M
$3.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, PEPTONIC medical achieved revenue of $2.8M and an EBITDA of -$5.4M.
PEPTONIC medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PEPTONIC medical valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 56% | XXX | XXX | XXX |
| EBITDA | XXX | -$5.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -193% | XXX | XXX | XXX |
| EBIT | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -151% | XXX | XXX | XXX |
| Net Profit | XXX | -$6.2M | XXX | XXX | XXX |
| Net Margin | XXX | -223% | XXX | XXX | XXX |
| Net Debt | XXX | $0.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PEPTONIC medical's stock price is SEK 0 (or $0).
PEPTONIC medical has current market cap of SEK 24.3M (or $2.5M), and EV of SEK 33.1M (or $3.4M).
See PEPTONIC medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4M | $2.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PEPTONIC medical has market cap of $2.5M and EV of $3.4M.
PEPTONIC medical's trades at 1.2x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate PEPTONIC medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PEPTONIC medical's P/E ratio is not available.
See valuation multiples for PEPTONIC medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5M | XXX | $2.5M | XXX | XXX | XXX |
| EV (current) | $3.4M | XXX | $3.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPEPTONIC medical's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $2.9M for the same period.
PEPTONIC medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PEPTONIC medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PEPTONIC medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -193% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 207% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PEPTONIC medical acquired XXX companies to date.
Last acquisition by PEPTONIC medical was XXXXXXXX, XXXXX XXXXX XXXXXX . PEPTONIC medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is PEPTONIC medical headquartered? | PEPTONIC medical is headquartered in Sweden. |
| How many employees does PEPTONIC medical have? | As of today, PEPTONIC medical has 2 employees. |
| Is PEPTONIC medical publicy listed? | Yes, PEPTONIC medical is a public company listed on SAT. |
| What is the stock symbol of PEPTONIC medical? | PEPTONIC medical trades under PMED ticker. |
| When did PEPTONIC medical go public? | PEPTONIC medical went public in 2014. |
| Who are competitors of PEPTONIC medical? | Similar companies to PEPTONIC medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PEPTONIC medical? | PEPTONIC medical's current market cap is $2.5M |
| Is PEPTONIC medical profitable? | Yes, PEPTONIC medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
